| 000 | 01650nam a2200361 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223025923.0 | ||
| 008 | 090908s2009 ua d f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.08.08.M.Sc.2009.Im.S | ||
| 100 | 0 | _aIman Mohamed Higazy | |
| 245 | 1 | 2 |
_aA study of the transdermal bioavailability of tenoxicam / _cIman Mohamed Higazy ; Supervised Mahmoud M. Ghorab , Hussein O. Ammar , Soheir A. Elnahhas |
| 246 | 1 | 5 | _aدراسة التوافر الحيوى لدواء التينوكسيكام عبر الجلد |
| 260 |
_aCairo : _bIman Mohamed Higazy , _c2009 |
||
| 300 |
_a316 P. : _bcharts ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics | ||
| 520 | _aThis thesis deals with designing new transdermal formulation for tenoxicam characterized by safety and high therapeutic efficacy. This would be achieved via utilizing proniosomes and lyotropic liquid crystals as new transdermal systems. In addition, the effect of newly developed penetration enhancers on the permeation of tenoxicam across the skin is also considered | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aLyotropic liquid crystals | |
| 653 | 4 | _aProniosomes | |
| 653 | 4 | _aTenoxicam | |
| 700 | 0 |
_aHussein Osman Ammar , _eSupervisor |
|
| 700 | 0 |
_aMahmoud Mohamed Ghorab , _eSupervisor |
|
| 700 | 0 |
_aSoheir Abdallah Elnahhas , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 902 | _a1 | ||
| 905 |
_aMustafa _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c23576 _d23576 |
||